Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Cytogenetic risk & the impact of daratumumab in myeloma

Luciano Costa • 15 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Daratumumab
APOLLO CANDOR CASTOR

Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, highlights results of a meta-analysis determining the impact of daratumumab in the treatment of multiple myeloma according to cytogenetic risk. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Luciano Costa

CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma 4:04
CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma
Luciano Costa • 13 Dec 2024
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT 4:50
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT
Luciano Costa • 13 Dec 2024
Elranatamab vs real-world treatments in triple-class refractory myeloma: insights from MagnetisMM-3 3:24
Elranatamab vs real-world treatments in triple-class refractory myeloma: insights from MagnetisMM-3
Luciano Costa • 13 Dec 2024
Strategies to optimize the outcomes of earlier-line patients treated with CAR T-cell therapy 3:01
Strategies to optimize the outcomes of earlier-line patients treated with CAR T-cell therapy
Luciano Costa • 26 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals